Publication: Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash
| dc.contributor.author | Chantarangsu S. | |
| dc.contributor.author | Mushiroda T. | |
| dc.contributor.author | Mahasirimongkol S. | |
| dc.contributor.author | Kiertiburanakul S. | |
| dc.contributor.author | Sungkanuparph S. | |
| dc.contributor.author | Manosuthi W. | |
| dc.contributor.author | Tantisiriwat W. | |
| dc.contributor.author | Charoenyingwattana A. | |
| dc.contributor.author | Sura T. | |
| dc.contributor.author | Takahashi A. | |
| dc.contributor.author | Kubo M. | |
| dc.contributor.author | Kamatani N. | |
| dc.contributor.author | Chantratita W. | |
| dc.contributor.author | Nakamura Y. | |
| dc.date.accessioned | 2021-04-05T03:35:08Z | |
| dc.date.available | 2021-04-05T03:35:08Z | |
| dc.date.issued | 2011 | |
| dc.date.issuedBE | 2554 | |
| dc.description.abstract | Background. We aimed to identify disease-predisposing variations with nevirapine-induced rash using genome-wide single-nucleotide polymorphisms (SNPs) as genetic markers. Methods. A genome-wide association study (GWAS) was performed using-550000 markers in 72 human immunodeficiency virus (HIV)-infected Thai patients with nevirapine-induced rash and 77 nevirapine-tolerant patients, and then candidate SNPs were further evaluated in a replication set (88 patients with nevirapine-induced rash and 145 nevirapine-tolerant patients). Results. The genome-wide association analysis and replication studies of candidate SNPs identified significant associations of nevirapine-induced rash with 2 SNPs (rs1265112 and rs746647) within CCHCR1 on chromosome 6p21.3 (P GWAS = 1.6 × 10 -4; P replication = 2.6 × 10 -5; P combined = 1.2 × 10 -8). The odds ratio (OR) of the risk genotypes under a dominant model was 4.36 (95% confidence interval [CI], 2.58-7.36). The noncoding SNPs rs1265112 and rs746647 were in complete linkage disequilibrium with the nonsynonymous SNP rs1576 (r 2 5 1.00), which has been associated with psoriasis. The logistic regression analysis also indicated genetic variations in CCHCR1 to be significantly associated with rash, with an OR of 2.59 (95% CI, 1.82-3.68; P = .007). The receiver operating characteristic curve showed that the algorithm had an area under the curve of 76.4%, which was developed with 5 factors: rs1576*G status, HLA-B*3505 status, not receiving prescribed lead-in of nevirapine, history of drug allergy, and CD4 cell count prior to the nevirapine treatment. Conclusions. We demonstrated that genetic variations in CCHCR1 are strongly associated with nevirapineinduced rash. A predictive model that includes genetic and clinical risk factors for nevirapine-associated rash might be useful in lowering the incidence of rash associated with nevirapine initiation among HIV-infected patients. © The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.citation | Clinical Infectious Diseases. Vol 53, No.4 (2011), p.341-348 | |
| dc.identifier.doi | 10.1093/cid/cir403 | |
| dc.identifier.issn | 10584838 | |
| dc.identifier.other | 2-s2.0-79961219567 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14740/7265 | |
| dc.rights.holder | มหาวิทยาลัยศรีนครินทรวิโรฒ | |
| dc.subject.other | Coiled coil alpha helical rod protein1 | |
| dc.subject.other | Nevirapine | |
| dc.subject.other | Peptides and proteins | |
| dc.subject.other | Unclassified drug | |
| dc.subject.other | Case control study | |
| dc.subject.other | CD4 lymphocyte count | |
| dc.subject.other | Chromosome 6p | |
| dc.subject.other | Controlled study | |
| dc.subject.other | Disease predisposition | |
| dc.subject.other | Disease severity | |
| dc.subject.other | Drug eruption | |
| dc.subject.other | Drug hypersensitivity | |
| dc.subject.other | Drug tolerance | |
| dc.subject.other | Genetic association | |
| dc.subject.other | Genetic variability | |
| dc.subject.other | Human | |
| dc.subject.other | Human immunodeficiency virus infected patient | |
| dc.subject.other | Human immunodeficiency virus infection | |
| dc.subject.other | Major clinical study | |
| dc.subject.other | Medical history | |
| dc.subject.other | Nucleotide sequence | |
| dc.subject.other | Priority journal | |
| dc.subject.other | Psoriasis | |
| dc.subject.other | Retrospective study | |
| dc.subject.other | Review | |
| dc.subject.other | Single nucleotide polymorphism | |
| dc.subject.other | Thailand | |
| dc.subject.other | Anti-HIV Agents | |
| dc.subject.other | Chromosomes, Human, Pair 6 | |
| dc.subject.other | Drug Eruptions | |
| dc.subject.other | Genetic Predisposition to Disease | |
| dc.subject.other | Genome-Wide Association Study | |
| dc.subject.other | HIV Infections | |
| dc.subject.other | Humans | |
| dc.subject.other | Intracellular Signaling Peptides and Proteins | |
| dc.subject.other | Lamivudine | |
| dc.subject.other | Logistic Models | |
| dc.subject.other | Nevirapine | |
| dc.subject.other | Polymorphism, Single Nucleotide | |
| dc.subject.other | Retrospective Studies | |
| dc.subject.other | Risk Factors | |
| dc.subject.other | ROC Curve | |
| dc.subject.other | Stavudine | |
| dc.subject.other | Thailand | |
| dc.title | Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash | |
| dc.type | Review | |
| dspace.entity.type | Publication | |
| swu.datasource.scopus | https://www.scopus.com/inward/record.uri?eid=2-s2.0-79961219567&doi=10.1093%2fcid%2fcir403&partnerID=40&md5=0b64c693b382dfa274a5aee57deb8421 |
